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Soluble latent membrane-type 1 matrix metalloproteinase se-
creted by human mesangial cells is activated by urokinase.
Background. Matrix metalloprotease 2 (MMP2) is secreted in a
latent inactive form (pro-MMP2) that is activated on the cell
surface by a membrane-type 1 MMP (MT1-MMP) in the presence
of the tissue inhibitor of MMP (TIMP2). In spite of evidence for
the synthesis of MT1-MMP shown by immunoblotting, immuno-
cytochemistry and RT-PCR, and of TIMP2, MMP2 was found
exclusively in a latent form in human mesangial cells (HMC)
serum-free culture medium.
Methods and Results. On purified membranes of HMC, MT1-
MMP was found in a 63 kD latent form and as a faint band of 55
kD. The 55 kD band was also present in the ultracentrifuged
conditioned medium and likely represented MT1-MMP cleaved
from its transmembrane domain, since Northern blot analysis
showed only one transcription product. The addition of urokinase
plasminogen activator (uPA, 100 nM) to HMC membranes in-
duced the activation of pro-MMP2 via the activation of latent
membrane-associated MT1-MMP as reflected by the cleavage of
the 63 and 55 kD forms. In addition, when the conditioned
medium was successively incubated with uPA and a2-macroglob-
ulin and analyzed by immunoblotting, MT1-MMP decreased,
indicating that the soluble MT1-MMP was in a latent form and
was activated by uPA.
Conclusion. Our results provide the first evidence, to our
knowledge, of the existence of a soluble latent form of MT1-MMP
secreted by primary human cells in culture, confirming that
MT1-MMP is an ectoenzyme, and show that uPA can regulate
MT1-MMP activity in a soluble phase.
The integrity of the extracellular matrix is a critical
parameter in glomerular function. Proteinuria, due to an
increase of the permeability of the glomerular basement
membrane on the one hand, and mesangial expansion
leading to glomerulosclerosis and renal failure on the other
hand, are two major hallmarks of glomerular disease. In
both cases, a dysregulation of the activity of proteolytic
enzymes, particularly matrix metalloproteases (MMPs),
and of the plasminogen activator system may be implicated
[reviewed in 1, 2]. Several studies have demonstrated
matrix degrading enzymes in human and rat glomeruli and,
in particular, the existence of MMP2 (gelatinase A, 72 kD)
and of MMP9 (gelatinase B, 92 kD) [3–6]. MMP2 and
MMP9 have attracted much attention because they de-
grade type IV collagen, which is a major component of
physiological basement membranes and extracellular ma-
trices. MMP2 and MMP9 are secreted in a latent inactive
form and their mechanisms of activation are still unclear.
MMP2 activation was reported to be dependent on a newly
discovered membrane-type MMP, MT1-MMP, in contrast
to previous reports suggesting a role of plasmin [7, 8] and of
urokinase [9]. Because mesangial cells play a central role in
glomerular fibrosis, their proteolytic potential has been the
focus of numerous studies. Under basal conditions, mesan-
gial cells in culture secrete only MMP2 and no urokinase
[10, 11], findings that are consistent with immunohisto-
chemical studies of kidney tissue showing the expression of
MMP2 [12] but not of urokinase by mesangial cells [13, 14].
In addition to its collagen-degrading activity, it has been
recently suggested that active MMP2 may play a role in the
proliferation and in the inflammatory phenotype of rat
mesangial cells [15]. However, MMP2 is produced in a
latent form by human mesangial cells in spite of the recent
demonstration of MT1-MMP [16], in contrast to rat mes-
angial cells where MT1-MMP is absent [15]. Several lines
of evidence indicate that MT1-MMP was also secreted in a
latent inactive form [17, 18], but the mechanism of activa-
tion of latent MT1-MMP has not yet been elucidated. Since
in pathological conditions such as inflammation uPA can be
generated in large quantities in the mesangium by infiltrat-
ing neutrophiles and monocytes/macrophages, we ques-
tionned whether uPA could play a role in the activation of
pro-MT1-MMP, and therefore in MMP2 activation, thus
supporting the recent data of Turck et al [15]. Our study
shows that uPA was able to induce the activation of
pro-MMP2 secreted by human mesangial cells in the
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presence of cells as well as in a cell-free system, and thus in
the absence of the membrane-associated form of MT1-
MMP. Urokinase activation of MMP2 in the absence of
cells was mediated by the activation of a latent soluble form
of MT1-MMP, confirming that MT1-MMP is an ectoen-
zyme.
METHODS
Reagents
RPMI 1640, fetal calf serum (FCS), trypsin, agarose and
the enzyme for reverse transcription were from GIBCO
BRL (Gaithersburg, MD, USA); L-glutamine, collagenase
type I and human thrombin were from Sigma Chemical Co
(St Louis, MO, USA); human high molecular weight uroki-
nase was from Hoechst-Behring (Puteaux, France) and
recombinant tPA was from Boehringer Mannheim (Mann-
heim, Germany); human a2-macroglobulin was from Cal-
biochem (La Jolla, CA, USA). The molecular weight
standards for the SDS-PAGE gels were from Bio-Rad
(Hercules, CA, USA); human recombinant pro-MMP2,
monoclonal antibodies to human MMP2 [Ab-3] and to
MT1-MMP [Ab-1 clone 114-1F2 (Sato et al [17]) were
obtained from Oncogene Science (Genzyme, Cambridge,
MA, USA). Monoclonal antibodies to the active site of
human uPA (MuK4) were from Biopool (Umeå, Sweden)
and to the uPA receptor (uPAR) were from American
Diagnostica Inc. (Greenwich, CT, USA). The ECL kit, the
goat anti-mouse IgG and (a-32P) dCTP were purchased
from Amersham Life Science (Buckinghamshire, UK). All
other reagents were of analytical grade.
Cell culture
Human glomerular mesangial cells (HMC) were isolated
as described previously [10], cultured in RPMI 1640 con-
taining 2 mM L-glutamine and 10% heat inactivated FCS,
and characterized as reported [10]. The cells were used
between passes two and four. The human fibrosarcoma HT
1080 cell line was obtained from American Type Culture
Collection (ATCC, Rockville, MD, USA) and the cells
were grown in DMEM containing 5% inactivated FCS and
2 mM L-glutamine. Conditioned medium of subconfluent
mesangial cells was obtained after washing the cells and
incubating them in serum-free RPMI 1640 in the presence
or in the absence of plasminogen activators. At the end of
the incubation period, the conditioned medium was with-
drawn, centrifuged 15 minutes at 14,000 g or for some
experiments ultracentrifuged two hours at 35,000 g and
stored at 230°C until analysis. Conditioned medium was
concentrated 25 times with Amicon centriprep columns
(Witten, Germany).
Membrane preparation
Plasma membranes were prepared from HT 1080 and
from mesangial cells. Briefly, the cells were washed in cold
Krebs-Heinseleit buffer (118 mM NaCl, 5 mM KCl, 1.1 mM
MgSO4, 2.5 mM CaCl2, 1.2 mM KH2PO4, 25 mM NaHCO3,
pH 7.4), resuspended in homogenization buffer (5 mM
Tris-HCl pH 7.4, containing 0.25 M sucrose, 1 mM EGTA,
500 units/ml of Trasylol, and 1 mM PMSF) and homoge-
nized at 4°C in a 50-ml Potter homogenizer. Three ml of
the homogenate was loaded onto 2 ml of 1.45 M sucrose in
20 mM Tris-HCl, pH 7.4 and centrifuged at 35,000 g for 30
minutes in a Beckman SW 28 rotor. The membranes at the
interface were collected, pelleted for 20 minutes at 40,000
g and washed three times in 10 mM HEPES pH 7.4,
containing 0.25 M sucrose, 5 mM MgCl2, 0.2 mM CaCl2, 250
units/ml of Trasylol and 0.5 mM PMSF. The membranes
were resuspended in the same buffer and stored at 280°C.
Gelatin zymography and reverse zymography
Gelatinolytic activity of the conditioned media was visu-
alized by SDS-polyacrylamide gels (7.5% PAGE, unless
otherwise stated) containing 1 mg/ml gelatin. After electro-
phoresis, the gels were soaked in Triton X100 2.5% for one
hour and incubated in Tris-HCl 50 mM pH 7.5, CaCl2 5 mM,
ZnCl2 1 mM overnight at 37°C and stained with Coomassie
Blue dye. Reverse gelatin zymography was performed by
incubating the gels in the same buffer containing 1 volume
of HT 1080 serum-free conditioned medium for 24 hours at
37°C.
Immunoblot analysis
After electrophoresis on SDS-PAGE, the proteins were
transferred onto PVDF membrane (Millipore) with a
Trans-Blot semi-dry transfer cell (Bio-Rad). After blocking
one hour at 37°C in 2% bovine serum albumin in Tris 50
mM pH 7.5, NaCl 100 mM (TBS) containing 0.1% Tween
20, the membrane was incubated with antibodies to MMP2
(1 mg/ml) or to MT1-MMP (10 mg/ml) for 18 hours at 4°C.
After extensive washing in TBS 0.1% Tween 20, the goat
anti-mouse IgG was added and the incubation prolonged
for one hour at room temperature. The blots were revealed
by chemoluminescence with the ECL kit.
Immunogold silver staining (IGSS)
Mesangial cells grown on cover slips were fixed in 1.25%
glutaraldehyde in phosphate buffer saline (PBS, 0.13 M
NaCl, 2.6 mM KCl, 1.4 mM KH2PO4, 4 mM Na2HPO4) for 10
minutes and rinsed in PBS. The cells were incubated with
anti-human MT1-MMP (10 mg/ml) in PBS containing 1%
bovine serum albumin (PBS-BSA), overnight at 4°C. After
washing in PBS-BSA, the cells were incubated with gold-
labeled (1 nm) anti-mouse IgG for three hours at room
temperature. The slides were washed in distilled water
before amplification with a silver enhancement reagent at
room temperature, and counterstained with Giemsa. Pho-
tographs were taken with combined brightfield and epipo-
larization microscopy.
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Northern blot analysis
Total RNA was isolated using the guanidium isothiocya-
nate method [19]. Twenty micrograms of total RNA were
analyzed by Northern blot using a 32P-labeled 550 bp
human MT-MMP cDNA obtained by RT-PCR (see below).
The membranes were hybridized overnight at 42°C, washed
in 0.2 3 SSC 0.1%SDS twice for 15 minutes at room
temperature then twice at 42°C and finally at 65°C.
Amplification of MT1-MMP mRNA from HMC by
RT-PCR
The RNA messenger from HMC and HT 1080 was
reverse transcribed using random hexamers. Twenty-five
nanograms of cDNA were used as a template in a PCR
reaction. The sense primer 59-CCCTATGCCTACATC-
CGTGA-39, corresponding to nucleotides 598 to 617 of
human MT1-MMP and the antisense primer 59-TCCATC-
CATCACTTGGTTAT-39, complementary to nucleotides
1129-1148 of human MT1-MMP were used as described
[20]. PCR was performed by standard techniques using Taq
polymerase, repeating 35 cycles of a 60-second denatur-
ation step at 94°C, a 60-second annealing step at 60°C and
a 60-second extension step at 72°C. The reaction amplified
a 550-bp product which was analyzed on a 1.5% agarose
gel. The mesangial cell PCR products of 10 reactions were
combined, eluted and used as a probe for Northern analysis
after sequencing.
Pro-MMP2 purification
Latent MMP2 was purified from HMC serum-free con-
ditioned media. After SDS-PAGE electrophoresis, the gel
was cut at position 68 kD band and pro-MMP2 was
electro-eluted. The recovery of a latent form of MMP2 was
further assessed by gelatin zymography and immunoblot-
ting.
RESULTS
Mesangial cells secrete pro-MMP2, a membrane-
associated pro-MT1-MMP, a membrane furin-processed
MT1-MMP and a soluble pro-MT1-MMP
Human mesangial cells in culture secrete only MMP2 in
a latent form, identified by a single lysis band with an
apparent molecular weight of 68 kD on gelatin zymograms
in culture media (Fig. 1A). Even in serum-free conditioned
media of 48 hours, no lysis band of lower molecular weight
indicative of MMP2 activation was visible (not shown). It is
well established [4, 21], and we also confirmed by reverse
gelatin zymography (Fig. 1B), that human mesangial cells
in culture secrete TIMP2. The results of immunoblot
analysis of a HMC membrane preparation (Fig. 2A), of
RT-PCR (Fig. 2B) and of immunogold silver staining (Fig.
2D) demonstrated that HMC also synthesize MT1-MMP.
In addition, Northern blot analysis showed only one tran-
script at the expected size of 4.5 kb (Fig. 2C). Immunoblot
analyses of HMC membrane preparation showed two ma-
jor bands that were always present, one at 63 kD that was
specific for membrane-associated pro-MT1-MMP [22, 23],
one at 45 kD [24], and a minor band at 55 kD. The 55 kD
band occasionally observed associated with the membranes
(Fig. 3, lane 1) could represent the furin-matured MT1-
MMP [23] but could also correspond to latent MT1-MMP
truncated at the transmembrane domain [24, 25] and being
secreted in the conditioned medium. To test this hypothe-
sis, we performed immunoblot analyses of the serum-free
conditioned medium of HMC with a monoclonal antibody
to human MT1-MMP. The results confirmed the existence
of a soluble 55 kD protein in the concentrated ultracentri-
fuged serum-free conditioned medium (Fig. 3, lane 2). This
55 kD MT1-MMP could not be ascribed to alternative
splicing since only one transcript was detected by Northern
blot.
Fig. 1. Human mesangial cells secrete inactive
latent form of MMP2 and TIMP2. (A) The
gelatinolytic activity of the serum-free
conditioned medium of human mesangial cells
and of HT 1080 cells were analyzed in a 7.5%
SDS-PAGE gel containing 1 mg/ml gelatin and
incubated as described in the text. The
gelatinolytic activity was visualized by
Coomassie blue staining. (B) Visualization of
TIMPs activities by reverse gelatin zymography
analysis in a 14% SDS-PAGE gel. The
molecular weight markers are on the left.
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Activation of pro-MMP2 by addition of uPA to mesangial
cells
Next we investigated the role of tPA and uPA on the
generation of active MMP2. The uPA, but not tPA, could
induce the activation of pro-MMP2, as shown by the
appearance of a gelatinolytic band at 62 kD (Fig. 4). The
activation of latent MMP2 by uPA was time-dependent
(Fig. 5A). In the presence of 100 nM uPA, the activated
forms of MMP2 were detectable after two hours of incu-
bation at 37°C and after 24 hours, 30% of pro-MMP2 was
activated. The activation of pro-MMP2 by uPA was also
dose-dependent (Fig. 5B). The activation of MMP2 could
be detected by zymography with 100 nM uPA, and this
effect reached a plateau for 500 nM uPA, a concentration at
which 50% of pro-MMP was cleaved. No further activation
of MMP2 was observed even after prolonged incubation
with uPA (not shown). Since mesangial cells secrete plas-
minogen activator inhibitor type 1 (PAI-1) and also possess
the uPA receptor that mediates the internalization and
degradation of uPA/PAI-1 complexes [26], we wanted to
Fig. 2. Evidence for the synthesis of MT1-MMP by human mesangial cells. (A) Immunoblotting of human mesangial cells (HMC) membrane
preparations from two different origins and from HT 1080 cells stimulated or not by PMA (5 nM) as a control (SDS-10% PAGE). The results showed
two major bands at 63 and 45 kD in both cells types. (B) RT-PCR as described in the text. (C) Northern blot analysis of MT1-MMP mRNA in HMC.
(D) Immunogold silver staining of HMC. MT1-MMP was detected in a granular pattern as bright blue staining on the surface of mesangial cells.
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study the role of uPA binding to its specific receptor on the
activation of pro-MMP2. The results showed no modifica-
tions of pro-MMP2 activation in the presence of antibodies
blocking uPA-uPA receptor interactions, indicating that
uPA binding to its receptor was not necessary. In contrast,
addition of antibodies to the active site of uPA totally
prevented the appearance of active forms of MMP2, indi-
cating that the active site of uPA was necessary to pro-
MMP2 activation (not shown). Next, we questionned
whether the absence of total activation of pro-MMP2 could
be due to the inhibition of active exogenous uPA by PAI-1
secreted by HMC, during the incubation period. The fibrin
zymography confirmed the persistence of active uPA after
24 hours of incubation with HMC (not shown). Therefore
the lack of total conversion of pro-MMP2 into active
MMP2 was not due to active uPA exhaustion.
uPA activation of pro-MMP2 in the conditioned medium
is mediated by activation of latent soluble MT1-MMP
Surprisingly, the activation of pro-MMP2 from HMC by
uPA could be observed in the absence of cells. The
incubation of uPA with ultracentrifuged serum-free condi-
tioned media induced MMP2 activation to the same extent
as that in the presence of cells (Fig. 6). To further study the
effect of uPA on pro-MMP2, we incubated recombinant
proenzyme-MMP2 with uPA at 37°C up to 24 hours. By
gelatin zymography, no activation of pro-MMP2 could be
observed (Fig. 7, lane 4), confirming the absence of direct
cleavage of pro-MMP2 by uPA [27, 28]. In contrast,
addition of ultracentrifuged serum-free conditioned me-
dium to uPA and pro-MMP2 induced pro-MMP2 activa-
tion (Fig. 7, lane 5). One could argue that the higher
concentration of pro-MMP2 in lane 5 could account for
MMP2 auto-activation, as reflected by the lower lysis band,
but the pro-MMP2 concentration was similar to that in lane
1 where no activation was observed. These results suggest
that uPA had activated the latent soluble MT1-MMP,
which in turn had activated pro-MMP2.
To confirm this hypothesis and distinguish between
activated and latent proteinases we took advantage of the
property of a2-macroglobulin to form complexes with pro-
teolytically active, but not with latent or inactive proteases.
This test is based on the well documented finding that
a2-macroglobulin cannot bind to inactive proteinases [29].
Therefore, we incubated the conditioned medium with or
without uPA (100 nM) for 24 hours at 37°C, followed by the
addition of excess a2-macroglobulin (100 mg/ml) and the
incubation was prolonged for one hour. The conditioned
media were analyzed by immunoblotting. The results
showed in the control conditioned medium incubated with
a2-macroglobulin one strong band of 55 kD corresponding
to soluble MT1-MMP, whereas in the conditioned medium
preincubated with uPA and then with a2-macroglobulin,
the 55 kD band was hardly visible, suggesting that soluble
MT1-MMP had been activated and trapped by a2-macro-
globulin (Fig. 8A). No complexes of MT1-MMP/a2-macro-
globulin could be visualized because it did not enter the gel
under non reducing conditions. To strenghthen these re-
sults, the conditioned media were also analyzed for the
molecular forms of MMP2 by immunoblotting (Fig. 8B).
The results showed one single band of 66 kD representing
latent MMP2 in the control conditioned medium incubated
with a2-macroglobulin. In contrast, in the presence of uPA
and a2-macroglobulin, two bands of 66 and 62 kD were
visible, corresponding to active and activated and cleaved
forms of MMP2. The extremely low level of staining of
these two bands confirms that MMP2 has been activated
Fig. 3. Evidence for a soluble MT1-MMP in the conditioned medium of
mesangial cells. Immunoblot analysis after electrophoresis by SDS-7.5%
PAGE. Lane 1, HMC membranes showing the existence of the major 63
and 45 kD bands and a faint band of 55 kD; Lane 2, the ultracentrifuged
conditioned medium of HMC concentrated 25 times by Amicon; Lane 3,
HT 1080 cells membranes as control.
Fig. 4. Addition of uPA to mesangial cells induces the appearance of
activated MMP2. uPA (100 nM) was added to serum-starved HMC and
incubated for 24 hours, and the conditioned media were analyzed by
gelatin zymography. As compared to control, the addition of uPA, but not
of tPA, could induce the appearance of activated form of MMP2.
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and trapped by a2-macroglobulin (Fig. 8B). All together,
these results indicated that soluble MT1-MMP was in
latent form and was activated by uPA and that pro-MMP2
activation by uPA in the conditioned medium was mediated
by the activation of soluble MT1-MMP.
Effect of uPA on membrane associated MT1-MMP
To study the effects of uPA on latent membrane-associ-
ated MT1-MMP, mesangial cell membranes were incu-
bated with uPA 100 nM at 37°C for 15 minutes up to 24
hours, and the molecular form of MT1-MMP analyzed by
immunoblot (Fig. 9). In the presence of uPA, the 63 kD and
55 kD bands of membrane-associated MT1-MMP progres-
sively disappeared, and the intensity of the 45 kD band
remained unchanged even after 24 hours of incubation with
uPA. These results suggested that incubation with uPA
provoked MT1-MMP activation followed by further degra-
dation either due to uPA or to MT1-MMP autoproteolysis
into lower molecular weight degradation products [18, 30].
DISCUSSION
Pro-MMP2 activation can be achieved in vitro by multi-
ple ways. Autocatalysis may be observed in soluble phase
for high concentrations of pro-MMP2 [15, 27, 31], and it
has been recently demonstrated that pro-MMP2 activation
could depend on a membrane-associated MMP, MT1-
MMP [17, 24]. MT1-MMP would serve to concentrate
MMP2 on the cell surface where pro-MMP2 may undergo
activation by autocatalysis [32] after limited proteolysis by
active MT1-MMP [18, 33, 34], or would be activated via the
formation of a trimolecular complex with MT1-MMP and
TIMP2 [33, 34]. The relationship between MT1-MMP
structure and function has been extensively studied with a
particular interest for the transmembrane domain. Contra-
dictory results concerning the capacity of the transmem-
brane domain-deleted mutants to activate pro-MMP2 have
been reported [17, 18, 23, 24], although several lines of
evidence showed that this domain is not necessary for
activation of pro-MMP2 [18, 23]. Even though the discrep-
ancies may be explained by different experimental condi-
tions, it is likely that pro-MMP2 activation is not an
unequivocal process.
As for the cleavage of MT1-MMP from the cell surface,
the mechanism of its activation is still unclear. Will et al
have shown that trypsin, a serine protease, was effective in
vitro for the activation of a soluble catalytic domain of
MT1-MMP [18], and Strongin et al have shown the exis-
tence of a functional activated 60 kD form of MT1-MMP in
HT 1080 fibroblastic cell line [34]. The latter authors
suggested that serine proteases such as plasmin or plasmin-
ogen activators might be good candidates for the activation
of latent MT1-MMP. Since HT 1080 are known to secrete
large amounts of urokinase and some tPA [35, 36], it is
likely that one of these plasminogen activators was respon-
sible for the activation of pro-MT1-MMP. An interaction
between uPA and the metalloprotease proteolytic pathways
has been suggested for a long time [9, 37]. Although the
synthesis of uPA by human mesangial cells in culture
remains controversial, some authors claiming that there
was no synthesis of uPA [10, 11] whereas others have
Fig. 5. Time course and dose-dependent
generation of active MMP2 in the presence of
uPA. (A) Serum-deprived HMC were incubated
with uPA (100 nM), the conditioned media
withdrawn at intervals and analyzed by gelatin
zymography in a SDS-7.5% PAGE. A very faint
band of activated MMP2 can be seen after two
hours of incubation of HMC with uPA. The 54
kD lysis band was due to uPA since it was
visible with uPA alone (not shown). (B) Serum-
deprived HMC were incubated with uPA (0.1,
1, 10, 100, 500, 1000 nM). The conditioned
media were withdrawn after six hours of
incubation at 37°C and analyzed by gelatin
zymography, as described before.
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demonstrated the contrary [7], in our experimental condi-
tions, human mesangial cells in culture do not synthesize
uPA. They synthesize a little tPA that is complexed to
plasminogen activator inhibitor-1 in the conditioned me-
dium [10]. Therefore, mesangial cells constitute a good
model to study the effect of uPA on pro-MMP2 and
MT1-MMP activation. The fact that uPA but not tPA nor
plasmin (personal observation) could activate MT1-MMP
is of major importance given the recent data of a close
correlation between active MMP2 and the inflammatory
phenotype of rat mesangial cells in vitro [15]. Turck et al
have shown that rat mesangial cells transfected with MMP2
antisense RNA had a reduced proliferation rate and that
reconstitution with active MMP2 restored the proliferating
rate [15]. These data are further supported by the in vivo
data of increased MMP2 mRNA and activity, associated
with increased glomerular cellularity in anti-Thy 1.1 glo-
merulonephritis in rat [12] and in sclerotic murine glomer-
uli from mice transgenic for the bovine growth hormone
[38]. Human mesangial cells with an “activated” phenotype
can be encountered in vivo in acute glomerulonephritis
associated with mesangial cell proliferation and expression
of smooth-muscle alpha actin, and with uPA production in
large quantities by infiltrating cells, neutrophils and mono-
cytes/macrophages. In these pathological conditions, uPA
may play a crucial role in activating pro-MMP2 via activa-
tion of MT1-MMP. Our results support the recent data of
Mazzieri et al [39], who found that urokinase plays a role in
the activation of pro-MMP2, but we could not demonstrate
the role of uPA/uPA receptor interaction on MMP2 acti-
vation, nor could we reproduce the activation of pro-
MMP2 by plasmin.
The existence of a soluble form of MT1-MMP has been
suspected by Okada et al, who found in human carcinomas
that MT1-MMP transcripts were detected in stromal cells
but not in cancer cells, whereas the protein was detected in
cancer cells [40]. Therefore, they suggested that MT1-
MMP may be an ectoenzyme generated by cleavage at the
cell surface. Imai et al have described the secretion, in the
culture medium of a human breast carcinoma cell line
stimulated with Concanavalin A, of a 56 kD propeptide-
deleted MT1-MMP complexed to TIMP2 [25]. MT1-MMP
would have been processed at the cell surface, then com-
plexed to TIMP2, and the complex released in the condi-
tioned medium after pro-MMP2 activation. This may not
be the case for human mesangial cells since we were unable
to detect any active MMP2 in basal conditions. Further-
more, Cao et al have observed in the culture medium of
COS cells transfected with a MT1-MMP deletion mutant
lacking the transmembrane domain, the presence of a 54
kD protein recognized by two different antibodies to
MT1-MMP [24]. Taken together with the reports of Pei
and Weiss [23] and of Cao et al [24], our data strongly
suggest that MT1-MMP exists in at least three forms:
membrane-associated, furin-processed, and soluble MT1-
MMP. The latter is a latent form and needs a cooperating
factor(s) to be activated. The role of uPA on soluble
MT1-MMP activation may have important physiological
implication, since recently Sawicki et al have described a
new pathway of platelet aggregation involving MMP2 [41].
They showed that the platelet releasate contained latent
MMP2. However, platelet aggregation was induced by
active but not latent MMP2, and the mechanism of MMP2
activation has not been elucidated. Since active uPA is
associated to platelet membranes [42], it is possible that
membrane-bound and soluble MT1-MMP activation by
uPA may occur at the platelet surface or in a close vicinity,
thus allowing the activation of pro-MMP2 released from
the platelets. These issues are currently under investigation.
In conclusion, we have shown the existence of a soluble
latent form of MT1-MMP secreted by primary human
mesangial cells in culture, thus confirming that MT1-MMP
is an ectoenzyme. We have also shown that uPA can
Fig. 6. Active MMP2 generation by uPA in a cell-free system. The
molecular forms of MMP2 in the conditioned medium of HMC in the
presence of uPA added to the cells or to the ultracentrifuged conditioned
medium were analyzed (A) by immunoblotting and (B) by zymography.
Lane 1, conditioned medium of serum-starved HMC; Lane 2, conditioned
medium of HMC incubated with uPA (100 nM) for 24 hours; Lane 3,
ultracentrifuged conditioned medium incubated with uPA (100 nM) for 24
hours. The molecular weight markers are on the left.
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activate latent membrane-associated and soluble MT1-
MMP.
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APPENDIX
Abbreviations used in this article are: FCS, fetal calf serum; HMC,
human mesangial cells; IGSS, immunogold silver staining; MMP2, matrix
metalloprotease 2; MT1-MMP, membrane-type 1 matrix metalloprotease;
PAI-1, plasminogen activator inhibitor type-1; PBS-BSA, phosphate buff-
ered saline-bovine serum albumin; RT-PCR, reverse transcribed-poly-
merase chain reaction; TIMP, tissue inhibitor of matrix metalloprotease;
tPA, tissue plasminogen activator; uPA, urokinase plasminogen activator;
uPAR, urokinase plasminogen activator receptor.
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